natgillin/translations-raw huggingface dataset:
Subkutan anvendelse Klinisk virkning
Subcutaneous use Clinical efficacy
Subkutan anvendelse Kvæg:
Subcutaneous use Cattle:
Subkutan anvendelse pulver og solvens: i fyldt pen (glas)
Subcutaneous use Powder and solvent:
Subkutan anvendelse Pulver: hætteglas (glas)
powder: vial (glass);
Subkutan anvendelse Pulver: hætteglas (glas)
Subcutaneous use
Subkutan anvendelse Subkutan
Subcutaneous use
Subkutan anvendelse Subkutan anvendelse
Subcutaneous use
Subkutan anvendelse Subkutan anvendelse
use Subcutaneous use Subcutaneous use Subcutaneous use
Subkutan anvendelse Én gang ugentligt
Subcutaneous use Once weekly
Subkutan anvendelse Én gang ugentligt.
Subcutaneous use Once weekly.
Subkutan anvendelse,
Subcutaneous use, intramuscular use
Subkutan anvendelse, in-ovo anvendelse
Subcutaneous use, in-ovo use
Subkutan anvendelse, intramuskulær
Route of administration
Subkutan anvendelse, intramuskulær
Subcutaneous use, intramuscular use
Subkutan anvendelse, intramuskulær anvendelse
Route of administration
Subkutan anvendelse, intramuskulær anvendelse
Subcutaneous use, intramuscular use
Subkutan anvendelse, intravenøs anvendelse og intramuskulær anvendelse
Subcutaneous use, intramuscular use or intravenous use
Subkutan anvendelse.
Subcutaneous use - SC
Subkutan brug
Subcutaneous use.
Subkutan brug.
Subcutaneous use
Subkutan eller
Subcutaneous
Subkutan eller
Subcutaneous or
Subkutan eller
Subcutaneous or intravenous use
Subkutan eller
Subcutaneous use
Subkutan eller
use Subcutaneous
Subkutan eller dermal blødningf Blå mærkerg
Subcutaneous or dermal bleedingf, Bruising g
Subkutan eller dermal blødningh, udslæt, pruritus
Subcutaneous or dermal bleedingh, Rash, Pruritus
Subkutan eller intramuskulær brug
Subcutaneous or intramuscular use
Subkutan eller intravenøs
Subcutaneous or
Subkutan eller intravenøs anvendelse
Subcutaneous or intravenous use
Subkutan eller intravenøs anvendelse
Subcutaneous use or intravenous use
Subkutan eller intravenøs anvendelse Læs indlægssedlen før brug.
Subcutaneous or intravenous use Read the package leaflet before use.
Subkutan eller intravenøs anvendelse Læs indlægssedlen inden brug
Subcutaneous or intravenous use Read the package leaflet before use.
Subkutan eller intravenøs anvendelse; Intramuskulær anvendelse
Subcutaneous or intravenous use, Intramuscular use
Subkutan eller intravenøs injektion
Route of administration
Subkutan eller intravenøs injektion; Intramuskulær anvendelse
Subcutaneous or intravenous injection, Intramuscular use
Subkutan formulering
Herceptin Subcutaneous
Subkutan formulering i injektionssystem
SC formulation in administration system
Subkutan indgift af 0,001 mg/kg/dag til rotter og 0,005 mg/kg intravenøst en gang hver 2-3 dag til hunde i indtil 52 uger blev også fint tolereret.
Administration of 0.001 mg/kg/day subcutaneously in rats and 0.005 mg/kg intravenously once every 2–3 days in dogs for up to 52 weeks was also well tolerated.
Subkutan indgift af 0,001 mg/kg/dag til rotter og 0,005 mg/kg intravenøst en gang hver 2–3 dag til hunde i indtil 52 uger blev også fint tolereret.
Administration of 0.001 mg/kg/day subcutaneously in rats and 0.005 mg/kg intravenously once every 2–3 days in dogs for up to 52 weeks was also well tolerated.
Subkutan indgivelse
Subcutaneous route
Subkutan indgivelse af produktet kan fremkalde forbigående lokal hævelse på injektionsstedet samt betændelsesreaktioner, som forsvinder inden for 14 dage efter behandling.
Subcutaneous administration of the product may induce transient local swelling at the injection site as well as inflammatory reactions which resolve within 14 days post treatment.
Subkutan indgivelse.
Subcutaneous route
Subkutan infusion som hjemmebehandling skal iværksættes og initialt monitoreres af en læge eller sygeplejerske med erfaring i at vejlede patienter om hjemmebehandling.
Subcutaneous infusion for home treatment should be commenced and initially monitored by a healthcare professional experienced in the guidance of patients for home treatment.
Subkutan Injection
Subcutaneous use
Subkutan injektion
Subcutaneous
Subkutan injektion
Subcutaneous administration:
Subkutan injektion
Subcutaneous injections:
Subkutan injektion
Subcutaneous route
Subkutan injektion
Subcutaneous use
Subkutan injektion
Subcutaneous use.
Subkutan injektion (kvæg) Intramuskulær injektion (svin)
Subcutaneous use (cattle), intramuscular use (pigs)
Subkutan injektion (kvæg) Intramuskulær injektion (svin)
Subcutaneous use(cattle), intramuscular use (pigs)
Subkutan injektion af Fertavid kan udføres af patienten selv eller dennes partner, forudsat de har modtaget fyldestgørende instruktioner af lægen.
Using the pen injector, injection of Fertavid can be carried out by the patient, provided that proper instructions are given by the physician.
Subkutan injektion af Puregon kan udføres af patienten selv eller dennes partner, forudsat de har modtaget fyldestgørende instruktioner af lægen.
Using the pen, injection of Puregon can be carried out by the patient, provided that proper instructions are given by the physician.
Subkutan injektion af Toujeo er en forudsætning for den lange virkningsvarighed.
The prolonged duration of action of Toujeo is dependent on its injection into subcutaneous tissue.
Subkutan injektion i nakken eller intramuskulær injektion i brystet af 1 dosis af 0,25 ml.
s.c. injection or i.m. injection of one dose of 0.25 ml.
Subkutan injektion i nakken eller intramuskulær injektion i brystet af 1 dosis af 0,25 ml.
Subcutaneous injection in the neck or intramuscular injection in the breast of one dose of 0.25 ml.
Subkutan injektion:
Subcutaneous administration:
Subkutan og
Subcutaneous
Subkutan og
Subcutaneous and
Subkutan og
Subcutaneous or
Subkutan og intramuskulær administration tolereres godt hos kvæg og grise; kun hos mindre end 10 % af behandlet kvæg i kliniske studier sås let og forbigående hævelse på injektionsstedet efter subkutan injektion.
In cattle and pigs, subcutaneous as well as intramuscular administration is well tolerated; only a slight transient swelling at the injection site following subcutaneous administration was observed in less than 10 % of the cattle treated in clinical studies.
Subkutan og intravenøs
intravenous use Subcutaneous or
Subkutan og intravenøs
Route of
Subkutan og intravenøs
Subcutaneous or
Subkutan og intravenøs
Subcutaneous use
Subkutan og intravenøs anvendelse
Subcutaneous or intravenous use
Subkutan og intravenøs injektion
Subcutaneous or intravenus use
Subkutan, intramuskulær administration tolereres godt; kun hos mindre end 10 % af behandlet kvæg i kliniske studier sås let og forbigående hævelse på injektionsstedet efter subkutan injektion.
Subcutaneous and intramuscular administration is well tolerated; only a slight transient swelling at the injection site following subcutaneous administration was observed in less than 10 % of the cattle treated in clinical studies.
Subkutan, intramuskulær eller intravenøs injektion
Subcutaneous, intramuscular or intravenous use
Subkutan, intramuskulær og intravenøs administration tolereres godt af kvæg og svin; hos mindre end 10 % af kvæg, som blev behandlet i kliniske studier, forekom lette, forbigående hævelser på injektionsstedet efter subkutan injektion.
In cattle and pigs, subcutaneous, intramuscular as well as intravenous administration is well tolerated; only a slight transient swelling at the injection site following subcutaneous administration was observed in less than 10 % of the cattle treated in clinical studies.
Subkutan, intramuskulær og intravenøs administration tolereres godt hos kvæg og grise; kun hos mindre end 10 % af behandlet kvæg i kliniske studier sås let og forbigående hævelse på injektionsstedet efter subkutan injektion.
In cattle and pigs, subcutaneous, intramuscular as well as intravenous administration is well tolerated; only a slight transient swelling at the injection site following subcutaneous administration was observed in less than 10% of the cattle treated in clinical studies.
Subkutan, intramuskulær og intravenøs administration tolereres godt hos kvæg og svin; kun hos mindre end 10% af behandlet kvæg i kliniske studier sås let og forbigående hævelse på injektionsstedet efter subkutan injektion.
In cattle and pigs, subcutaneous, intramuscular as well as intravenous administration is well tolerated; only a slight transient swelling at the injection site following subcutaneous administration was observed in less than 10 % of the cattle treated in clinical studies.
Subkutan, intramuskulær og intravenøs administration tolereres godt hos kvæg og svin; kun hos mindre end 10% af behandlet kvæg i kliniske studier sås let og forbigående hævelse på injektionsstedet efter subkutan injektion.
In cattle and pigs, subcutaneous, intramuscular as well as intravenous administration is well tolerated; only a slight transient swelling at the injection site following subcutaneous administration was observed in less than 10% of the cattle treated in clinical studies.
Subkutan, intramuskulær og intravenøs injektion tolereres godt; kun hos mindre end 102 % af behandlet kvæg i kliniske studier sås let og forbigående hævelse på injektionsstedet efter subkutan injektion.
Subcutaneous, intramuscular as well as intravenous administration is well tolerated; only a slight transient swelling at the injection site following subcutaneous administration was observed in less than 10 % of the cattle treated in clinical studies.
Subkutan, intramuskulær, intravenøs anvendelse
Route of administration
Subkutan, intramuskulær, intravenøs anvendelse
Subcutaneous, intramuscular, intravenous use
Subkutan, intravenøs og intraarteriel anvendelse.
Subcutaneous, intravenous and intraarterial use.
Subkutan, intravenøs, intramuskulær anvendelse
Subcutaneous, intramuscular, intravenous use
Subkutanblødning
Haemorrhage subcutaneous
subkutane
disorders
Subkutane injektioner af Relistor på 150 mg/kg/dag nedsatte rotters fertilitet.
Subcutaneous injections of Relistor at 150 mg/kg/day decreased fertility in rats.
Subkutane regimener med 140 mg hver anden uge og 420 mg én gang om måneden var ækvivalente i den gennemsnitlige sænkning af LDL-C (gennemsnitligt uge 10 og 12), hvilket resulterede i -72 % til -57 % fra baseline sammenlignet med placebo.
Subcutaneous regimens of 140 mg every 2 weeks and 420 mg once monthly were equivalent in average LDL-C lowering (mean of weeks 10 and 12) resulting in -72 to -57% from baseline compared with placebo.
subkutane væv
disorders
subkutane væv
Skin and subcutaneous tissue disorders
subkutane væv
subcutan
subkutane væv
subcutaneous
subkutane væv
system disorders
subkutane væv
ubcutaneous
Subkutant
Subcutaneous use
Subkutant brug
Route of Administration Subcutaneous use
Subkutant brug
Subcutaneous use
Subkutant hormonimplantat
Subcutaneous hormonal implant
Subkutant Lispro (18 E)
SC Lispro (18 U)
Subkutant.
S.C.
suboptimal darunavir Cmin.
Indinavir
Suboxone 16 mg/4 mg sublinguale resoribletter
Suboxone 16 mg/4 mg sublingual tablets
Suboxone 16 mg/4 mg sublinguale resoribletter buprenorphin/naloxon
Suboxone 16 mg/4 mg sublingual tablets buprenorphine / naloxone
Suboxone 16 mg/4 mg sublinguale resoribletter buprenorphin/naloxon
Suboxone 16 mg/4 mg sublingual tablets buprenorphine/naloxone
Suboxone 2 mg/0,5 mg sublinguale resoribletter
Suboxone 2 mg/0.5 mg sublingual tablets
Suboxone 2 mg/0,5 mg sublinguale resoribletter buprenorphin/naloxon
Suboxone 2 mg/0.5 mg sublingual tablets buprenorphine / naloxone
Suboxone 2 mg/0,5 mg sublinguale resoribletter buprenorphin/naloxon
Suboxone 2 mg/0.5 mg sublingual tablets buprenorphine/naloxone
Suboxone 8 mg/2 mg sublinguale resoribletter
Suboxone 8 mg/2 mg sublingual tablets
Suboxone 8 mg/2 mg sublinguale resoribletter buprenorphin/naloxon
Suboxone 8 mg/2 mg sublingual tablets buprenorphine / naloxone
Suboxone 8 mg/2 mg sublinguale resoribletter buprenorphin/naloxon
Suboxone 8 mg/2 mg sublingual tablets buprenorphine/naloxone
Substanser transporteret af P-glykoprotein eller andre transportere
Substances transported by P-glycoprotein or other transporters
Substanser, der inducerer CYP3A4-aktivitet, kan forøge metaboliseringen og nedsætte gefitinibs plasmakoncentration og derved reducere gefitinibs effekt.
Substances that are inducers of CYP3A4 activity may increase metabolism and decrease gefitinib plasma concentrations and thereby reduce the efficacy of gefitinib.
Substitionsterapi bør kun påbegyndes og administreres under supervision af en læge med erfaring i behandling af immundefekter.
Replacement therapy should be initiated and monitored under the supervision of a physician experienced in the treatment of immunodeficiency.
Substitionsterapi hos voksne, børn og unge (2-18 år) ved:
Replacement therapy in adults, children and adolescents (2-18 years) in:
Substitution af endogent væksthormon hos voksne med væksthormonmangel opstået i barndommen eller med debut i voksenalderen.
Replacement of endogenous growth hormone in adults with growth hormone deficiency of either childhood or adult-onset etiology.
Substitutioner blev observeret i kombination med andre opståede substitutioner ved NS3-position R155 eller D168.
Substitutions were observed in combination with other emergent substitutions at NS3 position R155 or D168.
Substitutioner, der kun blev observeret i kombinationer med andre opståede substitutioner ved en eller flere af NS3- positionerne 80, 122, 155 og/eller 168.
Substitutions only observed in combinations with other emerging substitutions at one or more of the NS3 positions 80, 122, 155 and/or 168.
Substitutioner, der medførte daclatasvir-resistens i genotype 1-4, blev observeret i NS5A’s aminosyreregion N-terminal 100 i et cellebaseret replikon-system.
Substitutions conferring daclatasvir resistance in genotypes 1-4 were observed in the N-terminal 100 amino acid region of NS5A in a cell-based replicon system.
Substitutionerne blev korreleret med forskellige niveauer af nedsat enfuvirtid følsomhed hos specifikke hiv site-directed mutanter.
These substitutions were correlated with varying levels of reduced enfuvirtide susceptibility in HIV site- directed mutants.
Substitutionsbehanding
Replacement therapy
Substitutionsbehandling hos voksne med udtalt mangel på væksthormon med ætiologisk debut enten i barndommen eller som voksen.
Replacement therapy in adults with pronounced growth hormone deficiency of either childhood- or adult-onset aetiology.
Substitutionsbehandling ved primær immundefekt (PID)
Replacement therapy in primary immunodeficiency (PID)
Substitutionsenzymet hjælper med at nedbryde GL-3 og forhindrer det i at hobe sig op i patientens celler.
The replacement enzyme helps to break down GL-3 and stops it building up in the patient’s cells.
Substitutionsterapi hos voksne samt børn og unge (0-18 år) ved:
Replacement therapy in adults, and children and adolescents (0-18 years) in:
Substitutionsterapi hos voksne, børn og unge (2-18 år) ved:
Replacement therapy in adults, children and adolescents (2-18 years) in:
Substitutionsterapi til voksne, børn og unge (0-18 år) med primære immundefektsyndromer såsom:
Replacement therapy in adults, children and adolescents (0-18 years) in primary immunodeficiency syndromes such as:
Substitutionsterapi ved myelomatose eller kronisk lymfatisk leukæmi med svær sekundær hypogammaglobulinæmi og recidiverende infektioner.
Replacement therapy in myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections.
Substitutionsterapi ved primær
Replacement therapy in primary immunodeficiency
Substitutionsterapi ved primær immundefekt
Replacement therapy in primary immunodeficiency
Substitutionsterapi ved primære immundefektsyndromer
Replacement therapy in primary immunodeficiency syndromes
Substitutionsterapi ved primære immundefektsyndromer (PID)
Replacement therapy in primary immunodeficiency (PID) syndromes
Substrater for brystcancer-resistent protein (BCRP) og P-glykoprotein
Breast cancer resistance protein (BCRP) and P-glycoprotein substrates
Substrater for OCT1
Substrates of OCT1
substrater.
Interaction (mechanism, if known)
substrater/hæmmere.
ORAL CONTRACEPTIVES
Substudie
Substudy
Succes efter 100 dage
Success at day 100
Succes efter 180 dage*
Success at day 180
Succes-rate* %
Success rate
Succesfuld global responsratea og mortalitet uanset årsag hos patienter med candidiasis i dybtliggende væv – samlet analyse
Rate of Successful Global Responsea and All-Cause Mortality in Patients with Deep Tissue Candidiasis – Pooled Analysis
Succesfuldt globalt respons ved EOIVTb
Global Response of Success at EOIVTb
Succesfuldt globalt respons ved EOTb
Global Response of Success at EOTb
Succesrate (%)
Success rate (%)
Succesraten for RIE- patienterne er vist i nedenstående tabel.
The success rates in RIE patients are shown in the table below.
Succesrigt respons er set hos 24 patienter (15 med fuldstændigt, 9 med delvist respons.
Successful response was seen in 24 patients (15 complete, 9 partial responses).
Successrate a n/N (%)
Success a rate n/N (%)
Succinylsyre indgår i Krebs’ cyklus, hvor det metaboliseres til kuldioxid og vand.
Succinic acid enters the Krebs cycle where it is metabolised to carbon dioxide and water.
Sucralose Anisaroma Vand, renset
Anise aroma Water, purified
Sucralose Sorbitol, flydende Glycerol (E 422)
Sucralose Sorbitol liquid Glycerol (E422)
Sufentanil udskilles i modermælk og kan give bivirkninger hos det ammede barn.
Sufentanil passes into breast milk and can cause side effects in the breast-fed child.
Sufentanils farmakokinetik efter sublingual administration kan beskrives som en trekammer-model med førsteordens absorption.
The pharmacokinetics of sufentanil after sublingual administration can be described as a three- compartment model with first-order absorption.
Suffolk CB9 8PU Storbritannien.
United Kingdom
Suffolk CB9 8PU Storbritannien‌
Suffolk CB9 8PU United Kingdom
Sug 1,8 ml af den medfølgende solvens op
Withdraw 1.8 ml of the supplied diluent.
Sug derpå den beregnede mængde Caelyx op i en steril sprøjte.
Take the appropriate volume of Caelyx up into a sterile syringe.
Sug det opløste produkt ud af glasset vha. en kanyle.
Using a hypodermic needle and syringe, draw the dissolved product out of the vial.
Sug en mængde luft svarende til den ordinerede Humalog Mix50-dosis op i sprøjten.
Draw air into the syringe equal to the prescribed Humalog Mix50 dose.
Sug hele indholdet af den opløste vaccine op i en steril sprøjte og indgiv hele indholdet subkutant.
Withdraw the entire contents of the reconstituted vaccine into a sterile syringe and administer the whole contents subcutaneously.
Sug indholdet i de to hætteglas op i applikatoren i overensstemmelse med brugsvejledningen i pakningen med applikatoren.
Draw the contents of the two vials into the administration device following the instructions for use in the device package.
Sug insulinskyen langsomt ind gennem munden i en dyb indånding.
Slowly and deeply breathe in the insulin cloud through your mouth in one breath.
Sugammadex kan administreres på flere forskellige tidspunkter efter administration af rocuronium- eller vecuroniumbromid:
Sugammadex can be administered at several time points after administration of rocuronium or vecuronium bromide:
Sugammadex kan anvendes under amning.
Sugammadex can be used during breast-feeding.
Sugammadex kan fjernes ved hæmodialyse ved brug af et højflux-filter, men ikke med et lavflux- filter.
Sugammadex can be removed using haemodialysis with a high flux filter, but not with a low flux filter.
SUI er utilsigtet tab af urin ved fysisk belastning eller i forbindelse med hoste, latter, nysen, løft eller gymnastik smerter som følge af diabetisk perifer neuropati (beskadigelse af nerverne i ekstremiteterne, som kan forekomme hos patienter med diabetes).
SUI is accidental leaks of urine during physical exertion or when coughing, laughing, sneezing, lifting or exercising; pain due to diabetic peripheral neuropathy (damage to the nerves in the extremities that can occur in patients with diabetes).
Suicidal adfærdb Suicidaltankerb Gennemført selvmordb
Suicidal behaviourb Suicidal ideationb Completed suicideb
Suicidaladfærd
Suicidal
Suicidaladfærd og/eller -tanker
Suicidal behaviour and/or ideation
Suicidalforsøg3, suicidaltanker3, psykose3, mani3, paranoia3, hallucinationer3, eufori3, affektlabilitet3, forvirret tilstand3, agitation3
suicide attempt3, suicide ideation3, psychosis3, mania3, paranoia3, hallucination3, euphoric mood3, affect lability3, confusional state3, aggression3
Suicidaltanker
behaviour
Suicidaltanker
Suicidal
Sukker (mindst 20 gram).
Sugar (at least 20 grams).
Sukker i urinen, øget urinmængde og hyppig vandladning
Glucose in urine, increased urine volume and frequency
Sukkersyge
Diabetes.
Sukkersyge (diabetes mellitus)
Sugar disease (diabetes mellitus)
Sukkersyge (diabetes) (symptomer omfatter overdreven tørst, kraftigt øget urinproduktion, øget appetit med vægttab, træthed, sløvhed, svaghedsfølelse, nedtrykthed, irritabilitet og generel utilpashed eller diabetisk ketoacidose (syrestoffer i blodet som følge af diabetes).
Diabetes (symptoms include excessive thirst, the passing of a greatly increased amount of urine, increase in appetite with a loss of weight, feeling tired, drowsy, weak, depressed, irritable and generally unwell) or diabetic ketoacidosis (acid in the blood produced from diabetes).
Sukkersyge (diabetes).
Diabetes.
Sukkersyge er en sygdom hvor din krop ikke producerer nok insulin til at kontrollere niveauet af dit blodsukker.
Diabetes is a disease where your body does not produce enough insulin to control the level of your blood sugar.
Sukkersyge er en sygdom hvor kroppen ikke producerer tilstrækkeligt insulin til at kontrollere blodsukkerniveauet.
Diabetes is a disease where your body does not produce enough insulin to control the level of your blood sugar.
Sukkersyge er en sygdom, hvor kroppen ikke danner tilstrækkelig insulin til at kontrollere dit blodsukkerniveau.
Diabetes is a disease where your body does not produce enough insulin to control the level of your blood sugar.
Sukkersyge.
Diabetes.
Sukkervataroma Dinatriumedetat Saltsyre
Cotton candy flavouring Disodium edetate Hydrochloric acid
Sukrose
Sucrose
Sukrose (som sammentrykkeligt sukker NF) Crospovidone
Sucrose (as compressible sugar NE) Crospovidone
Sulfamethoxazol+Trimethoprim2 800/160 mg, enkelt dosis
Sulfamethoxazole/Trimethoprim2 800/160, single dose
Sulfamethoxazol/ Trime-
Sulphamethoxazole/
sulfamethoxazol/trimethoprim
sulphamethoxazole/
Sulfamethoxazols AUC og Cmin:
Sulphamethoxazole AUC and Cmin: 
sulfasalazin
ulfasalazine
sulfasalazin (til behandling af inflammatoriske (betændelsesagtige) tarmsygdomme)
ulfasalazine (used to treat inflammatory bowel diseases)
sulfasalazin administreres sammen med Viekirax med eller uden dasabuvir
administered with Viekirax with or without dasabuvir.
Sulfasalazin, der bruges til at behandle inflammation/infektion i tarmen.
Sulfasalazine, used to treat inflammation/infection.
Sulfonamid (til behandling af infektioner)
Sulfonamides (used to treat infections).
Sulfonamid (til behandling af infektioner).
Sulfonamides (used to treat infections).
Sulfonamid (til behandling af infektioner).
Sulphonamides (used to treat infections).
Sulfonamider (til behandling af infektioner).
Sulfonamides (used to treat infections).
Sulfonamider (til behandling af infektioner).
Sulphonamides (used to treat infections).
sulfonamider – mod infektioner
ulphonamides – for infections
Sulfonylurea
Sulphonylurea
Sulfonylureas: Glucosekoncentrationerne faldt hos nogle raske forsøgspersoner, da glipizid administreredes samtidig med posaconazol.
Sulfonylureas: Glucose concentrations decreased in some healthy volunteers when glipizide was co- administered with posaconazole.
Sulfonylurinstof
Sulphonylurea
Sulfonylurinstof (glimepirid1)
Sulphonylurea (glimepiride1)
Sulfonylurinstof (såsom glimepirid eller glibenclamid).
Sulfonylurea (such as glimepiride or glibenclamide).
Sulfonylurinstoffer
Sulphonylureas
Sulfonylurinstoffer (f.eks. tolbutamid, glipizid og glyburid) (medicin mod diabetes)
Sulfonylureas (e.g., tolbutamide, glipizide and glyburide) (used for diabetes)
Sulfonylurinstoffer (f.eks. tolbutamid, glipizid og glyburid) (medicin mod diabetes)
Sulfonylureas (e.g., tolbutamide, glipizide, and glyburide) (used for diabetes)